Parameters | Groups | Days | ||
14 days | 28 days | 42 days | ||
T-SOD (U/ml) | Control group | 127.74 ± 4.15 | 150.91 ± 2.10 | 162.34 ± 3.14 |
High F group I | 127.48 ± 2.52 | 150.65 ± 2.69 | 161.92 ± 2.37 | |
High F group II | 102.25 ± 1.39** | 122.65 ± 1.93** | 145.77 ± 4.72** | |
High F group III | 101.56 ± 1.12** | 119.20 ± 2.20** | 140.91 ± 1.79** | |
GSH-Px (U/ml) | Control group | 544.70 ± 6.94 | 497.70 ± 5.33 | 442.57 ± 14.17 |
High F group I | 527.63 ± 11.06* | 483.51 ± 14.39 | 421.37 ± 11.12* | |
High F group II | 485.10 ± 4.95** | 382.90 ± 16.02** | 326.24 ± 10.19** | |
High F group III | 446.92 ± 13.87** | 348.97 ± 14.16** | 302.12 ± 6.55** | |
CAT (U/ml) | Control group | 8.24 ± 0.58 | 12.99 ± 0.75 | 13.76 ± 0.55 |
High F group I | 7.80 ± 0.36 | 12.39 ± 0.76 | 13.12 ± 0.77 | |
High F group II | 6.64 ± 0.52** | 9.34 ± 0.33** | 11.65 ± 0.51** | |
High F group III | 6.45 ± 0.50** | 8.17 ± 0.38** | 11.19 ± 0.57** | |
GSH (mgGSH/L) | Control group | 13.88 ± 0.71 | 16.96 ± 1.06 | 17.41 ± 0.65 |
High F group I | 13.61 ± 0.86 | 16.05 ± 0.61 | 16.60 ± 1.04 | |
High F group II | 11.57 ± 0.83** | 12.92 ± 0.93** | 13.78 ± 0.99** | |
High F group III | 11.02 ± 0.83** | 10.61 ± 0.73** | 11.83 ± 0.45** | |
MDA (nmol/ml) | Control group | 3.44 ± 0.18 | 3.84 ± 0.76 | 5.96 ± 0.09 |
High F group I | 3.64 ± 0.05 | 4.66 ± 0.03 | 6.45 ± 0.33* | |
High F group II | 5.03 ± 0.96** | 5.58 ± 0.85** | 6.73 ± 0.17** | |
High F group III | 5.27 ± 0.33** | 5.89 ± 0.46** | 8.90 ± 0.40** | |
The ability to inhibit hydroxyl radicals (U/ml) | Control group | 1357.86 ± 2.01 | 1361.47 ± 1.59 | 1362.05 ± 1.55 |
High F group I | 1356.67 ± 3.12 | 1357.80 ± 2.64 | 1360.33 ± 1.38 | |
High F group II | 1348.80 ± 0.18** | 1345.37 ± 3.59** | 1355.48 ± 0.98** | |
High F group III | 1345.24 ± 1.56** | 1344.64 ± 1.30** | 1350.09 ± 3.30** |